1. Synthesis and biological evaluation of new peroxo-bridged diosgenin derivatives
- Author
-
Fuhao Chu, Tianxin Xie, Jing Chen, Penglong Wang, Bing Xu, Wenqiang Yan, Rui Zhao, Yuzhong Zhang, and Haimin Lei
- Subjects
Pharmacology ,HBsAg ,010405 organic chemistry ,Diosgenin ,Transfection ,010402 general chemistry ,01 natural sciences ,0104 chemical sciences ,chemistry.chemical_compound ,Complementary and alternative medicine ,chemistry ,Toxicity ,Pharmacology (medical) ,Photosensitizer ,Cytotoxicity ,Eosin Y ,Lead compound ,Nuclear chemistry - Abstract
Objective In order to find lead compound with anti-HBV activity from peroxo-bridged diosgenin derivatives obtained with Eosin Y as the photosensitizer. Method Eosin Y was used as the photosensitizer to activate the oxygen in the air to synthesize novel diosgenin derivatives with peroxo-bridge. The structures of synthesized compounds were identified by NMR and HR-MS. Their cytotoxicity and antihepatitis B activity were evaluated via MTS assay and ELISA method, respectively. Results Six diosgenin derivatives were synthesized, three of which contained peroxo-bridge, and their structures were confirmed by spectroscopy. It showed that 5α,8α-peroxo-6-alkenyl-diosgenin (7) could suppress the production of HBsAg on transfected HepG2.2.15 cells at low-toxic concentration and the inhibition rate on HepG2.2.15 cells was 18.28% at 12.50 µg/mL, better than that of 3TC (7.30% at 12.50 µg/mL) and others. Conclusion Due to its lower cytotoxicity and potential anti-hepatitis B activity, compound 7 could be developed as the promising candidate of anti-hepatitis B drug. It also indicated that the peroxo-bridged derivatives had potential biological values for developing clinical agents.
- Published
- 2018